Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
Enliven Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Enliven Therapeutics's total assets was $910.22M at Jun 30, 2026. For fiscal 2025 it was $476.17M, up 46.2% from the year before. The highest annual figure on record is $476.17M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $476.17M | +46.2% |
| FY2024 | Dec 31, 2024 | $325.76M | +19.8% |
| FY2023 | Dec 31, 2023 | $271.87M | +226.4% |
| FY2022 | Dec 31, 2022 | $83.30M | -11.1% |
| FY2021 | Dec 31, 2021 | $93.65M | +3.1% |
| FY2020 | Dec 31, 2020 | $90.84M | +172.8% |
| FY2019 | Dec 31, 2019 | $33.30M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $910.22M | +80.6% |
| Q1 FY2026 | Mar 31, 2026 | $464.85M | +53.6% |
| Q4 FY2025 | Dec 31, 2025 | $476.17M | +46.2% |
| Q3 FY2025 | Sep 30, 2025 | $490.88M | +60.7% |
| Q2 FY2025 | Jun 30, 2025 | $503.89M | +54.1% |
| Q1 FY2025 | Mar 31, 2025 | $302.57M | -11.7% |
| Q4 FY2024 | Dec 31, 2024 | $325.76M | +19.8% |
| Q3 FY2024 | Sep 30, 2024 | $305.43M | +11.5% |
| Q2 FY2024 | Jun 30, 2024 | $327.04M | +13.4% |
| Q1 FY2024 | Mar 31, 2024 | $342.78M | +13.2% |
| Q4 FY2023 | Dec 31, 2023 | $271.87M | +226.4% |
| Q3 FY2023 | Sep 30, 2023 | $274.04M | +363.7% |
| Q2 FY2023 | Jun 30, 2023 | $288.50M | +346.1% |
| Q1 FY2023 | Mar 31, 2023 | $302.87M | +271.2% |
| Q4 FY2022 | Dec 31, 2022 | $83.30M | -11.1% |
| Q3 FY2022 | Sep 30, 2022 | $59.10M | -44.8% |
| Q2 FY2022 | Jun 30, 2022 | $64.67M | -10.8% |
| Q1 FY2022 | Mar 31, 2022 | $81.60M | -0.1% |
| Q4 FY2021 | Dec 31, 2021 | $93.65M | +3.1% |
| Q3 FY2021 | Sep 30, 2021 | $107.03M | +6.8% |
| Q2 FY2021 | Jun 30, 2021 | $72.47M | -34.9% |
| Q1 FY2021 | Mar 31, 2021 | $81.69M | -26.0% |
| Q4 FY2020 | Dec 31, 2020 | $90.84M | +172.8% |
| Q3 FY2020 | Sep 30, 2020 | $100.18M | – |
| Q2 FY2020 | Jun 30, 2020 | $111.32M | – |
| Q1 FY2020 | Mar 31, 2020 | $110.32M | – |
| Q4 FY2019 | Dec 31, 2019 | $33.30M | – |
See a number that looks wrong?